肝脏 ›› 2025, Vol. 30 ›› Issue (4): 485-489.

• 病毒性肝炎 • 上一篇    下一篇

HLA-Ⅱ类分子限制性乙型肝炎核心抗原特异性T细胞受体鉴定

甘一帆, 郑安琪, 廖宝林, 吴晓娜, 于乐成, 王战会   

  1. 510515 广州 南方医科大学南方医院感染内科(甘一帆,郑安琪,吴晓娜,王战会); 510440 广州医科大学附属市八医院肝病中心(廖宝林); 210002 南京大学医学院附属金陵医院(东部战区总医院)肝病中心暨感染病科(于乐成)
  • 收稿日期:2025-01-04 出版日期:2025-04-30 发布日期:2025-06-17
  • 通讯作者: 于乐成,Email: gslsycy@163.com;王战会,Email: wangzhh@smu.edu.cn
  • 基金资助:
    国家自然科学基金(81772600);广州市科技计划项目(2025A03J3733)

Identification of HLA-II-restricted HBcAg-specific T cell receptors

GAN Yi-fan1, ZHENG An-qi1, LIAO Bao-lin2, WU Xiao-na1, YU Yue-cheng3, WANG Zhan-hui1   

  1. 1. Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China;
    2. Center of Hepatology, Guangzhou Eighth People' s Hospital, Guangzhou Medical University,Guangzhou 510440, China;
    3. Center of Hepatology and Department of Infectious Disease, Jinling Hospital (General Hospital of Eastern Theater Command), School of Medicine, Nanjing University, Nanjing 210002, China
  • Received:2025-01-04 Online:2025-04-30 Published:2025-06-17
  • Contact: WANG Zhan-hui, Email: wangzhh@smu.edu.cn; YU Yue-cheng, Email: gslsycy@163.com

摘要: 目的 筛选和鉴定HLA-Ⅱ类分子限制性乙型肝炎核心抗原(HBcAg)特异性T细胞受体(TCR),为探索HBV感染者CD4+ T细胞功能及免疫治疗奠定基础。方法 用HBcAg肽库刺激急性乙型肝炎患者外周血单个核细胞,分选CD4+CD154+ T单细胞。扩增TCR α/β双链,进行高通量测序和双链配对。克隆TCR,经慢病毒包装后感染Jurkat-76-NFAT-GFP细胞,建立稳定表达TCR的细胞系,并与永生化B细胞系呈递的HBcAg肽库共培养,从而筛选HBcAg特异性TCR。通过矩阵HBcAg小肽库确定TCR所识别的具体表位肽。用HLA-Ⅰ类抗体阻断剂及表达不同组合形式HLA-Ⅱ类分子的K562细胞系确定TCR的HLA限制性。最后通过肽浓度梯度分析,确定TCR的功能性亲和力。结果 基于CD4+CD154+ T单细胞分选和TCR αβ双链扩增配对,从13个TCR克隆中成功筛选出4个TCR可识别HBcAg特异性表位肽(EYLVSFGVWIRTPPA)。HLA限制性分析表明,4个TCR均能识别DPA1*01:03/ DPB1*05:01、 DPA1*01:03/DPB1*21:01和DPA1*02:02/ DPB1*05:01所呈递的表位肽。功能性亲和力分析显示4个TCR与HBcAg特异性表位肽有较高的亲和力,EC50最高可达7.817 nM。结论 成功获得了4个与多种HLA-DP分子具有高功能性亲和力的HLA-II限制性HBcAg特异性TCR,为下一步基于HBcAg特异性TCR研究HBV感染者CD4+ T细胞功能变化特点和研发新的免疫治疗策略提供了可能的新管线。

关键词: T淋巴细胞受体, 乙型肝炎病毒, 乙型肝炎核心抗原, HLA限制性

Abstract: Objective To screen and identify human leukocyte antigen class Ⅱ (HLA-II) restricted hepatitis B core antigen (HBcAg) specific T cell receptor (TCR), laying the foundation for exploring CD4+T cell function and new potential immunotherapy in HBV-infected patients. Methods Peripheral blood mononuclear cells (PBMCs) from acute hepatitis B patient were stimulated with HBcAg peptide library, and CD4+CD154+T single cells were sorted. TCR α/β double strands were amplified and paired. The paired TCR packaged by lentiviral vectors infected Jurkat-76-NFAT-GFP cells, which further established stable TCR expression cell line. The co culture of HBcAg peptide library presented by immortalized B cell lines aimed to screen for HBcAg specific TCRs. The specific peptide recognized by TCRs was determined through the HBcAg peptide library matrix. The HLA restriction of TCRs were determined by using anti-HLA-I and K562 cell lines expressing different combinations of HLA class II molecules. Finally, the functional avidity of the TCRs was determined through peptide concentration gradient analysis. Results Based on CD4+CD154+T single-cell sorting and TCR α/β pairing, 4 HBcAg specific TCRs recognizing the same peptide (EYLVSFGVWIRTPPA) were successfully screened from 13 TCR clones. All 4 TCRs can recognize the peptide presented by DPA1*01:03/ DPB1*05:01, DPA1*01:03/DPB1*21:01and DPA1*02:02/ DPB1*05:01 expression K562 cells. Functional avidity analysis showed that 4 TCRs have high avidity, with EC50 of up to 7.817 nM. Conclusion HLA-DP restricted HBcAg specific TCRs with high functional avidity were successfully obtained, providing a new possible pipeline for the next step to study the functional changes of CD4+T cells in HBV infected patients and develop new immunotherapy strategies based on HBcAg specific TCRs.

Key words: T cell receptor, Hepatitis B virus, Hepatitis B core antigen, HLA restriction